Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
36.99
-1.51 (-3.92%)
At close: Jul 20, 2026, 4:00 PM EDT
36.83
-0.16 (-0.45%)
After-hours: Jul 20, 2026, 7:57 PM EDT
Vera Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Vera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $81.79. The average 1-year stock price forecast is 121.11% higher than the current stock price, while the lowest is $43 (+16.25%) and the highest is $125 (+237.93%).
Price Target: $81.79 (+121.11%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $100 | Buy | Maintains | $100 | +170.34% | Jul 8, 2026 |
| Wedbush | Wedbush | Hold Maintains $35 → $47 | Hold | Maintains | $35 → $47 | +27.06% | Jul 8, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $56 → $76 | Buy | Reiterates | $56 → $76 | +105.46% | Jul 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $110 → $125 | Buy | Reiterates | $110 → $125 | +237.93% | Jul 8, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 | Buy | Maintains | $70 | +89.24% | Jul 8, 2026 |
Financial Forecast
Revenue This Year
32.10M
Revenue Next Year
261.07M
from 32.10M
Increased by 713.23%
EPS This Year
-6.21
from -4.66
EPS Next Year
-3.86
from -6.21
EPS and Forward PE are based on non-GAAP adjusted numbers.